Research progress of neoadjuvant therapy in adenocarcinoma of the esophagogastric junction

Abstract

Fan Sunfu, Wang Xinbao. Research progress of neoadjuvant therapy in adenocarcinoma of the esophagogastric junction[J]. Journal of International Oncology, 2016, 43(1): 53-55.

［1］杨杰, 王占红, 陈砚凝, 等. 食管胃交界腺癌的研究进展［J］. 临床与实验病理学杂志, 2011, 27(1): 83-86. ［2］ Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20years followup of a randomized trial［J］. J Surg Oncol, 2002, 80(2): 72-78. DOI:10.1002/jso.10102. ［3］ Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOGdirected intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection［J］. J Clin Oncol, 2012, 30(19): 23272333. DOI:10.1200/JCO.2011.36.7136. ［4］ Willett CG. Results of radiation therapy in gastric cancer［J］. Semin Radiat Oncol, 2002, 12(2): 170175. DOI:10.1053/srao.2002.30819 . ［5］ Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)—report on 370 patients［J］. Int J Radiat Oncol Biol Phys, 1998, 42( 5):929-934. ［6］朱旭升, 姚学权, 刘福坤. 胃癌放疗的研究进展［J］. 中国肿瘤外科杂志, 2014, 6(3): 177-179. DOI:10.3969/j.issn.1674-4136.2014.03.012. ［7］ Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer［J］. N Engl J Med, 2006, 355(1): 11-20. DOI:10.1056/NEJMoa055531. ［8］ Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial［J］. J Clin Oncol, 2011, 29(13): 1715-1721. DOI:10.1200/JCO.2010.33.0597. ［9］应杰儿, 毛伟敏. 食管胃交界部腺癌的放化疗进展［J］. 癌症进展, 2012, 10(3): 237-242. DOI:10.3969/j.issn.16721535.2012.03.009. ［10］董跃华, 魏玉磊, 王大伟, 等. POX方案在贲门癌新辅助化疗中的临床观察［J］. 中国临床医生, 2014, 42(2): 44-46. DOI:10.3969/j.issn.1008-1089.2014.02.017. ［11］ Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers［J］. Cancer, 2006, 107(2): 221231. DOI:10.1002/cncr.21986. ［12］ Schwer AL, Ballonoff A, Mccammon R, et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and endresults study［J］. Int J Radiat Oncol Biol Phys, 2009, 73(2): 449-455. DOI:10.1016/j.ijrobp.2008.04.022. ［13］ Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(Radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with metaanalysis combining individual patient and aggregate data［J］. Eur J Cancer, 2013, 49(15): 3149-3158. DOI:10.1016/j.ejca.2013.05.029. ［14］ van Hagen P, Hulshof M, Van Lanschot J, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer［J］. N Engl J Med, 2012, 366(22): 2074-2084. ［15］范志勤, 孟涛. 术前新辅助放化疗对胃食管结合部癌手术和预后的影响［J］. 现代预防医学, 2012, 39(15): 4022-4025. ［16］ Stahl M, Walz MK, Stuschke M, et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction［J］. J Clin Oncol, 2009, 27(6): 851856. DOI:10.1200/JCO.2008.17.0506. ［17］ Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial［J］. Eur J Cancer, 2011, 47(3): 354-360. DOI:10.1016/j.ejca.2010.09.009. ［18］ Gronnier C, Piessen G, Mariette C. Diagnosis and treatment of nonmetastatic esophagogastric junction adenocarcinoma: what are the current options?［J］. J Visc Surg, 2012, 149(1): e23-33. DOI:10.1016/j.jviscsurg.2012.01.003. ［19］ Moehler M, AlBatran SE, Andus T, et al. German S3guideline "Diagnosis and treatment of esophagogastric cancer"［J］. Z Gastroenterol, 2011, 49(4): 461-531. DOI:10.1055/s-0031-1273201.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan.Research progress on the interaction between gut microbiota and radiation enteritis[J]. Journal of International Oncology, 2023, 50(4): 244-247.

Research progress of neoadjuvant therapy in adenocarcinoma of the esophagogastric junction

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments